fashion -WSS

fashion

author：Wikipedia 2025-09-30 00:49:44 - browse：7825

Eli Lilly headquarters — Kristoffer Tripplaar/AP

The drug giant Eli Lilly said Thursday that its diabetes drug Mounjaro helped patients with the condition lose 15.7% of their body weight in a clinical trial, a result that Wall Street analysts expect to pave the way for the therapy’s approval as a weight loss treatment.

Mounjaro is the latest drug in a class known as GLP-1s or incretins — the same class as Novo Nordisk’s Ozempic, which has become a sensation because of its ability to help patients lose weight. Mounjaro has shown the potential to lead to even greater weight loss than Ozempic, and industry experts expect that it will eventually generate many billions of dollars in annual sales. Analysts at SVB Securities projected in December that Mounjaro sales could reach $26.4 billion by 2030.

Eli Lilly on Thursday also announced quarterly earnings of $1.64 per share, adjusted for one-time items, slightly below analyst expectations, on sales of $6.96 billion. Sales were hurt because of a comparison to a year ago, when the company’s Covid-19 monoclonal antibodies were still on the market. Mounjaro sales for the first quarter were $586 million, largely for people with diabetes, compared to an analyst consensus of $433.2 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

Wikipedia

WSS

U.K. Biobank has 500,000 peoples' genome sequences available

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

J&J to emphasize cancer drugs, stop much of its vaccine research

Disappointing trial forces Pfizer to pivot on obesity medicine plans

New documents shed light on MD Anderson Cancer Institute feud

PBM reform efforts get punted in Congress

focus

fashion

hotspot

New air purifier tech could be key to improving indoor air quality

Flagship Pioneering launches a new biotech in two countries

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Medical records are filled with copy

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Alabama frozen embryo ruling has major implications for IVF clinics

Medical records are filled with copy

ReNAgade cuts staff seven months after raising $300 million

Wikipedia

With clinical trial data readouts, here's how to spot spin

In utero gene editing: an explainer

NIH study of ME/CFS points to clear biological hallmarks

With competition flaring, obesity drug hits goal in liver disease study

The Harvard botanist who searched for psychedelics in the Amazon

With competition flaring, obesity drug hits goal in liver disease study

knowledge

Wikipedia

focus

explore